BCG-medac Basisdokumentation - medac GmbH
BCG-medac Basisdokumentation - medac GmbH
BCG-medac Basisdokumentation - medac GmbH
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
66<br />
Hudson M.A., Ritchey J.k., catalona W.J., Brown e.J., Ratliff t.L. (1990)<br />
Comparison of the Fibronectin-binding Ability and Antitumor Efficacy of Various<br />
Mycobacteria<br />
Cancer Res ., 50: 3843-3847<br />
Hudson M.A., Brown e.J., Ritchey J.k., Ratliff t.L. (1991a)<br />
Modulation of fibronectin-mediated bacillus calmette guérin attachment to murine bladder<br />
mucosa by drugs influencing the coagulation pathways<br />
Cancer Res ., 51: 3726-3732<br />
Hudson M.A., yuan J.J., catalona W.J., Ratliff t.L. (1991b)<br />
Adverse impact of fibrin clot inhibitors on intravesical bacillus calmette-guérin therapy for<br />
superficial bladder tumors<br />
J . Urol ., 144: 1362-1364<br />
Hudson M.A., Herr H.W. (1995)<br />
Carcinoma In Situ Of The Bladder<br />
J . Urol ., 153; 564-572<br />
Huncharek M., kupelnick B. (2003)<br />
Impact of intravesical chemotherapy versus <strong>BCG</strong> immunotherapy on recurrence of superficial<br />
transitional cell carcinoma of the bladder . Metaanalytic reevaluation<br />
Am J Clin Oncol; 26(4): 402-407<br />
Hurle R., Losa A., Manzetti A., Lambo A. (1999)<br />
Intravesical Bacille Calmette-Guerin In Stage T1 Grade 3 Bladder Cancer Therapy: A 7-Year<br />
Follow-Up<br />
Urology, 54: 258-263<br />
Irie A., Iwamura M., kadowaki k., ohkawa A., Uchida t., Baba S. (2002)<br />
Intravesical instillation of bacille calmette-guérin for carcinoma in situ of the urothelium involving<br />
the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter<br />
Urology, 59 (1): 53-57<br />
Jakse G., Hall R., Bono A., Höltl W., carpentier P., Spaander J.,<br />
van der Meijden A.P.M., Sylvester R. (2001)<br />
Intravesical <strong>BCG</strong> in Patients with Carcinoma in situ of the Urinary Bladder: Long-term<br />
results of EORTC GU Group Phase II Protocol 30861<br />
Eur .Urol ., 40: 144-150<br />
Jewett H.J., Strong G.H. (1946)<br />
Infiltrating carcinoma of the bladder: Relation of depth of penetration of the bladder wall to<br />
incidence of local extention and metastases<br />
J . Urol ., 55: 366<br />
Jimenez-cruz J.F., Vera-Donoso c.D., Leiva o., Pampola M., et al., (1997)<br />
Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): multicenter<br />
trial comparing Bacille Calmette-Guerin and interferon-alpha .<br />
Urology, 50: 529-535<br />
kälble t., Möhring k., Ikinger U., et al. (1991)<br />
Intravesikale Rezidivprophylaxe beim oberflächlichen Harnblasenkarzinom mit <strong>BCG</strong> und KLH<br />
Urologe A, 30; 118-121<br />
kälblet., Beer M., Mendoza e., Ikinger U., Link M., et al. (1994)<br />
<strong>BCG</strong> vs . Interferon A zur Rezidivprophylaxe beim oberflächlichen Harnblasenkarzinom<br />
Urologe A, 33 133-137<br />
kantor A.F., McLaughlin J.k., curtis R.e., Flannery J.t., Fraumeni J.F. (1986)<br />
Risk of a second malignacy after cancers of the renal parenchyma, renal pelvis and ureter<br />
Cancer, 58: 1158<br />
kavoussi L.R., torrence R.J., Gillen D.P., Hudson M.A., Haaff e.o., Dresner S.M.,<br />
Ratliff t.L. (1988)<br />
Results of 6 weekly intravesical Bacillus Calmette-Guérin instillations on the treatment of<br />
superficial bladder tumors<br />
J . Urol ., 139, 935-940 .
Change language